FDA Form 483 and Warning Letter Statistics FY2016-FY2026
A 2026 analyst data report on FDA Form 483 and warning letter statistics, covering year-by-year enforcement trends, country-level data, most-cited GMP observations, and 6 named case studies including Intas, Emergent BioSolutions, and Philips Respironics.